Obadias Marquez, MD
Internal Medicine · Ooltewah, TNNPI 1174597546
Payments from drug & device makers
Across 1,309 payments — averaging $2125.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1.6M
- Modernatx, Inc.$673K
- AstraZeneca$203K
- Genentech, Inc.$137K
- Pfizer$67K
- Rhythm Pharmaceuticals, Inc.$21K
- plus $46K from 54 others
Across 5 payments — averaging $1041.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5K
- GSK$187
What the payments were for
- Food & beverage$23,114100%
- Education$690%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,782,494 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 172 | $178,533 |
| EliquisApixaban | 188 | $171,022 |
| OzempicSemaglutide | 105 | $147,788 |
| FarxigaDapagliflozin Propanediol | 90 | $87,163 |
| XareltoRivaroxaban | 85 | $80,934 |
| JardianceEmpagliflozin | 59 | $75,643 |
| TrulicityDulaglutide | 58 | $67,468 |
| Tresiba Flextouch U-200Insulin Degludec | 80 | $65,047 |
| Tresiba Flextouch U-100Insulin Degludec | 76 | $55,010 |
| RybelsusSemaglutide | 34 | $52,051 |
| GlyxambiEmpagliflozin/Linagliptin | 53 | $50,876 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $42,446 |
| MyrbetriqMirabegron | 43 | $40,771 |
| CreonLipase/Protease/Amylase | 11 | $40,040 |
| JanuviaSitagliptin Phosphate | 33 | $38,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,756 | $246,001230 claims |
| Novo NordiskOzempic, Rybelsus | $4,695 | $199,839139 claims |
| PfizerEliquis | $67,488 | $171,022188 claims |
| Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr, Stiolto Respimat | $260 | $142,274140 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $203,372 | $99,434107 claims |
| Johnson & JohnsonXarelto | $1,345 | $80,93485 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $586 | $76,00775 claims |
| AbbVieCreon, Linzess, Synthroid | $2,255 | $74,920153 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $263 | $54,79176 claims |
| Astellas Pharma US IncMyrbetriq | $145 | $40,77143 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $548 | $24,28817 claims |
| NovartisEntresto | $89 | $16,44915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Ooltewah
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
- Charles CrumpChattanooga$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.